Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03322657 · ClinicalTrials.gov registry record · Phase 4

Sugammadex Versus Neostigmine for Reversal of Rocuronium Neuromuscular

A Phase 4 study of Anesthesia and Neuromuscular Blockade, sponsored by The Cleveland Clinic.

Completed
Registry status
Phase 4
Development phase
69
Enrollment target
1
Study location

NCT03322657: Completed Phase 4 study of Anesthesia and Neuromuscular Blockade, sponsored by The Cleveland Clinic.

NCT03322657 is a Phase 4 study of Anesthesia and Neuromuscular Blockade that has completed, run by The Cleveland Clinic. The registered enrollment target is 69 participants, below the 109,409-participant average among 57 other Anesthesia trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03322657, a Phase 4 study of Anesthesia and Neuromuscular Blockade, has completed, sponsored by The Cleveland Clinic.

COMPLETED
Registry status
Phase 4
Development phase
69 participants
Enrollment target
1
Study location

Study Summary

The aim of this study is to evaluate whether the use of Sugammadex for reversing the neuromuscular blocking effects of rocuronium during neurointerventional procedures can speed recovery of neuromuscular function. Half of participates will receive Neostigmine with glycopyrrolate, while the other half will receive Sugammadex.

Primary Outcome

The primary outcome was a time-to-TOF ratio ≥ 0.9 after the administration of the reversal agent. The TOF ratio was measured in a continuous manner every 12 seconds from the administration of the reversal drug until TOF ratio ≥ 0.9 or until 90 minutes after administration of the reversal agent.

Interventions

  • DRUG Sugammadex
  • DRUG Neostigmine
  • DRUG Glycopyrrolate

Study Locations (1)

Ohio

  • Cleveland Clinic - Cleveland

Trial Details

FieldValue
Enrollment Target 69 participants
Start Date 2017-11-14
Est. Completion 2021-02-01
Phase Phase 4
The Cleveland Clinic

688 total trials

What the finished NCT03322657 record still lists

NCT03322657 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 69 participants, a relatively small participant target, below the 109,409-participant average among 57 other Anesthesia trials with a reported enrollment target (100% lower).

The record links to 2 conditions, with Anesthesia appearing as the primary indexed condition, and to 3 interventions - of which Sugammadex is the first listed.

NCT03322657 reports a single indexed study location in Ohio.

Frequently Asked Questions

What is clinical trial NCT03322657 about?

NCT03322657 is a clinical study titled "Sugammadex Versus Neostigmine for Reversal of Rocuronium Neuromuscular". The aim of this study is to evaluate whether the use of Sugammadex for reversing the neuromuscular blocking effects of rocuronium during neurointerventional procedures can speed recovery of neuromuscular function. Half of participates will receive Neostigmine with glycopyrrolate, while the other hal...

What is the current status of trial NCT03322657?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 69 participants. The study started on 2017-11-14. Estimated completion is 2021-02-01.

What conditions does trial NCT03322657 study?

This clinical trial studies the following conditions: Anesthesia, Neuromuscular Blockade.

What interventions are being tested in trial NCT03322657?

The interventions under investigation include: Sugammadex (DRUG), Neostigmine (DRUG), Glycopyrrolate (DRUG).

Who is sponsoring clinical trial NCT03322657?

This trial is sponsored by The Cleveland Clinic, which has 688 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03322657 being conducted?

This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Anesthesia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03322657's enrollment target sits among peer trials

69 23rd of 57 higher than 35 of 57 other Anesthesia trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Anesthesia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04020575 · 69 participants · Phase 1

    Autologous huMNC2-CAR44 or huMNC2-CAR22 T Cells for Breast Cancer Targeting Cleaved Form of MUC1 (MUC1*)

  • NCT04163614 · 69 participants · NA

    Blood Pressure Slopes and Ultrafiltration in Hemodialysis Patients

  • NCT04164641 · 69 participants · NA

    Noraxon myoRESEARCH™ Software Gait Analysis Evaluation and Orthotic Gait Correction in Reducing Diabetic Foot Ulceration Or Subsequent Amputation in Patients With a History of a Diabetic Foot Ulceration

  • NCT04493372 · 69 participants · NA

    Deciphering Preserved Autonomic Function After Spinal Cord Injury

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03322657, the US trial registry maintained by the National Library of Medicine. NCT03322657 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.